
Roche licences antiviral nucleoside from Atea
Under the agreement, Roche will pay US$350m in cash for ex US-distribution of Atea Pharmaceuticals antiviral Phase II candidate. Atea has the option...

3,000+ experts discuss bioeconomy globally
First editions of the summit took place in Berlin in 2015 and 2018. This year, due to the pandemic, it is not taking place in Berlin as...

Atriva Therapeutics gets €24m from EIB
According to Atriva Therapeutics, the proceeds allow the company to start Phase II testing of its oral MEK inhibitor ATR-002. In preclinical trails,...

Janssen presents one-shot COVID-19 vaccine data
Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine...

Angelini Pharma to take over Arvelle Therapeutics
Under the terms of the agreement, Angelini Pharma will acquire Arvelle Therapeutics in an all-cash transaction for a total consideration of up to...

Omnix Medical bags €10.8m from EIC Accerator Fund
The money for the trial comes from the EIC Accelerator, for which last year 38 companies with potential breakthrough innovations were selected to...

LSP leads €21m round into Neurent Medical
Galway-based medical device company Neurent Medical, which is focussed on chronic inflammatory diseases of the sinuses and nasal passages said it...